|
Q1 2021
Pulse On Progress Newsletter
|
Introduction
Transcelerate aspires for a future state where research and development is faster, more efficient and harnesses all the available information. We invision this happening three ways:
- Full participation across all stakeholders—clinical trial sponsors, sites, investigators, patients and their healthcare providers.
- Information is fully used to improve the overall quality, design and development process. We protect patients through shared, proactive safety science.
- Improving the execution of research and development through greater harmonization with the potential to conduct collaborative trials.
|
|
Newest Resources and Company Milestones
- BioCelerate’s SEND Harmonization Initiative published its second manuscript, co-authored in collaboration with the FDA as part of its Public-Private Partnership, in Chemical Research in Toxicology’s Computational Toxicology Special Edition. The article, "Leveraging the Value of CDISC SEND Datasets for Cross-Study Analysis:
Incidence of Microscopic Findings in Control Animals" highlights the potential of SEND datasets for cross-study analysis and proposes solutions to address the challenges of doing so currently.
- SCOPE 2021 finished on March 4 after three days filled with informative sessions related to the R&D and pharma industry. TransCelerate had the opportunity to present 10 sessions over the course of the conference covering many topics related to our solutions and initiatives. To read the in-depth recap of our sessions, click here.
- We welcomed Andrew Hudson (Roche), who is the new Chair for the TransCelerate Pharmacovigilance (PV) Steering Committee. He will be taking over for Paul Chang (Johnson & Johnson), who we would like to thank for his dedication as Chair over the last two years. The innovative and synergetic energy he has brought to the committee during his time within TransCelerate's leadership has been appreciated.
|
|
|
Pulse On Progress Updates
|
|
|
Enhance Drug Safety
Objective: Facilitate solutions that address a common set of challenges in drug safety surveillance such as engaging the public, collaborating with regulators, incorporating data and analytics, developing model approaches, and assessing the impact of efforts.
|
|
|
|
Blog Updates & The Spotlight
|
Check Out Our Blog
|
|
|
|
|
LEARN ABOUT WHAT WE'VE BEEN UP TO THIS QUARTER
|
|
|
|
|
|
Spotlight
|
|
|
|
|
INTELLIGENT AUTOMATION OPPORTUNITIES IN PHARMACOVIGILANCE INITIATIVE
We spoke with Kristof Huysentruyt (UCB) on how machine learning, natural language processing, and artificial intelligence (AI) are becoming more prevalent across the biopharmaceutical industry as well as the challenges the industry is facing in validating this technology.
|
|
|
|
|
|
Mark Your Calendars
TransCelerate leaders and Member Companies are invited to participate and present at many biopharmaceutical research industry conferences and meetings across the globe to provide a perspective on industry challenges and clinical trial issues. Take a peek at a few places we will be presenting early next year. For detailed information on speaker presentations, visit the events page on the TransCelerate website.
|
|
|
|
|
April 7-9, 2021
Pharma: Clinical
Virtual Attendance
|
|
|
|
|
April 7-9, 2021
Patients as Partners U.S.
Virtual Attendance
|
|
|
|
|
April 20-22, 2021
SCRS European Site Solutions Summit 2021
Virtual Attendance
|
|
|
|
|
May 20-23, 2021
DIA China
Suzhou, China
|
|
|
|
|
May 24-27, 2021
Pharma SUG
Virtual Attendance
|
|
|
|
|
June 7-9, 2021
ARCS Annual Meeting
Sydney, Australia
|
|
|
|
|
June 14-18, 2021
PHUSE Connect US 2021
Virtual Attendance
|
|
|
|
|
June 27 – July 1, 2021
DIA Global Annual Meeting
June 27 – July 1, 2021
|
|
|
|
|